{"success":true,"data":{"pressRelease":{"id":"157953","rtpr_id":"nPn5WJXsKa-20261001","ticker":"NKTR","exchange":"NASDAQ","all_tickers":["NKTR"],"title":"New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026","author":"PR Newswire","published_at":"2026-10-01T11:30:02.062Z","article_body":"New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026\nPR Newswire\n\nSAN FRANCISCO and VIENNA, Oct. 1, 2026\n\nRezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year\nof treatment in two dermatological indications, reinforcing the differentiated\nproperties of this novel Treg mechanism\n\nIn alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4\nmonths off treatment and in 63% at six months off treatment\n\nHair regrowth continued for 6 months off treatment with 19% of patients\nachieving SALT Score ≤10, an improvement from 7% at the end of 52 weeks of\ntreatment\n\nThird Phase 3 study in the global ZENITH AD program initiated, expanding the\nprogram into treatment-experiencedatopicdermatitispatients;\nPhase3ZENITHAAstudytoinitiate in early 2027\n\nCompanytohostconferencecallwithinvestorsandanalystsat8:00AMET/2:00 PM CET\n\nSAN FRANCISCO and VIENNA, Oct. 1, 2026 /PRNewswire/ -- Nektar Therapeutics\n(Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from\nthe Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at\nthe European Academy of Dermatology and Venereology (EADV) Congress 2026 in\nVienna, Austria in two oral presentation sessions.\n\nAt EADV 2026, data from the 52-week treatment extension cohort and the 6-month\noff-treatment period in the global Phase 2b REZOLVE-AA study in patients with\nsevere-to-very-severe alopecia areata are being presented by Dr. David\nRosmarin, Chair of Dermatology, Indiana University School of Medicine in an\noral presentation entitled\n\"Rezpegaldesleukin,aNovelRegulatoryTCell-InducingBiologic,Demonstrates\nEfficacy and Safety in Severe-to-Very-Severe Alopecia Areata: 52-Week Results\nfrom the Phase 2b REZOLVE-AA Study\" [link to presentation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3105107766&u=https%3A%2F%2Fwww.nektar.com%2Fwp-content%2Fuploads%2F2026%2F10%2FEADV-2026_Rosmarin_Rezpegaldesleukin_Rezolve_AA.pdf&a=link+to+presentation)\n].\n\n\"These data demonstrate that one year of treatment with rezpegaldesleukin can\nresult in lasting and even deepening hair regrowth with these same effects\ncontinuing for six months off-treatment in the majority of patients,\" said\nDavid Rosmarin, M.D., Chair of the Department of Dermatology and Associate\nProfessor of Dermatology at Indiana University School of Medicine. \"As a novel\nTreg-targeted mechanism, rezpegaldesleukin is designed to address the\nunderlying immune dysregulation in patients with alopecia areata. To date, we\nhave not seen this degree of both sustained benefit and further hair regrowth\nafter treatment cessation with existing systemic therapies for alopecia\nareata. These findings suggest that rezpegaldesleukin may offer a\nfundamentally different approach to managing this chronic disorder and could\nemerge as a preferred first-line treatment option in the future for patients\nseeking durable disease control.\"\n\nHighlights from 52-Week Results in REZOLVE-AA Phase 2b Study in Alopecia\nAreata (Including Off-Treatment Durability):\n\n * A total of 31 patients continued into a blinded 16-week treatment extension\nafter 36 weeks of initial treatment with 27 patients in the twice-monthly\nrezpegaldesleukin dose arms (low dose of 18 µg/kg, n=14) and (high dose of 24\nµg/kg, n=13).\n * As previously reported, continued rezpegaldesleukin treatment through Week 52\ndemonstrated clear and consistent separation from placebo on key measures of\nefficacy. From Week 36 to Week 52, 29% of patients at low dose and 31% of\npatients at high dose achieved new SALT Score ≤20 responses as compared to\nnone in the placebo arm. A SALT Score ≤20 is achieved when a patient has 80%\nor more of their scalp covered by hair.\n * SimilarEfficacy Demonstrated in Patients Irrespective of Duration of Current\nEpisode: A new subgroup analysis of all patients who entered the 52-week\ntreatment extension showed similar efficacy data regardless of current\nalopecia areata episode duration. SALT Score ≤20 responses were achieved by\n29% and 30% of patients whose current episode was less than four years and\nthose whose current episode was four years or longer, respectively.\n * Off-Treatment Durability: Patients treated for 52 weeks showed 75% (6/8)\nmaintenance of SALT Score ≤20 after 4 months off treatment and 63% (5/8)\nmaintenance of SALT Score ≤20 after 6 months off treatment.\n * Off-Treatment Deepening: SALT Score ≤10 responses deepened in the 6-month\noff-treatment follow-up period from 7% at the end of treatment at week 52 to\n19% after 6 months off treatment.\n * Potential for Less Frequent Monthly Dosing Beyond One Year of Treatment: Data\nsupport evaluation of monthly (Q4W) or quarterly (Q12W) dosing beyond the\n52-week twice-monthly (Q2W) induction dosing for patients who achieve a SALT\nScore ≤20.\n * Phase 3 Study to Initiate in Early 2027: ZENITH AA study will be conducted in\n850 patients with severe-to-very-severe alopecia areata with a primary\nendpoint of SALT Score ≤20 at Week 52.\nAlso, at EADV 2026, datafromthemaintenanceperiodoftheREZOLVE-ADstudy in\nmoderate-to-severe atopic dermatitis patients who were treated with monthly\nand quarterly dosing regimens for up to 52 weeks were presented by Dr. Thomas\nBieber, Professor, Department of Dermatology and Allergy, Ludwig-Maximilians\nUniversity Hospital, Munich, Germany in an oral presentation entitled\n\"RezpegaldesleukinProvidesDurableandDeepeningImprovementsintheSignsand\nSymptoms of Atopic Dermatitis with Monthly and Quarterly Dosing: Results from\nthe Phase 2b REZOLVE-AD Maintenance Part of Study\" [link to presentation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1963735054&u=https%3A%2F%2Fwww.nektar.com%2Fwp-content%2Fuploads%2F2026%2F10%2FEADV-2026_Silverberg_Rezpegaldesleukin_Rezolve_AD.pdf&a=link+to+presentation)\n].\n\n\"Rezpegaldesleukin demonstrated a high maintenance of response and further\ndeepening of response that speaks to the unique therapeutic approach of a\nregulatory Tcell agonist in patients with atopic dermatitis,\" said Thomas\nBieber, M.D., Ph.D., Professor, Department of Dermatology and Allergy,\nLudwig-Maximilians University Hospital, Munich, Germany. \"With both monthly\nand quarterly maintenance dosing, new and sustained responses were observed\nacross the key endpoints of EASI-75, vIGA-AD 0/1 and Itch NRS, with some\npatients achieving complete skin clearance, or EASI-100. These novel data\nsupport the ongoing Phase 3 studies and also highlight the importance of a\nTreg mechanism to address the heterogeneity of disease in atopic dermatitis\npatients.\"\n\nHighlights from Week 52 REZOLVE-AD Maintenance Period in Atopic Dermatitis:\n\n * DurabilityofTreatmentEffect: Q4W and Q12W dosing regimens resulted in\nsustained disease control for at least a 75% improvement in the Eczema Area\nand Severity Index (EASI-75), at least a 90% improvement in the Eczema Area\nand Severity Index (EASI-90), validated Investigator Global Assessment of\nAtopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS)\nresponse, with the 24 µg/kg Q4W and Q12W regimens showing the highest\nmaintenance of response at Week 52.\n * New and Deepening of Response Over Time: A meaningful proportion of patients\nachieved new EASI-75, EASI-90, Itch NRS and vIGA-AD 0/1 responses at Week 52,\nsupporting increased disease control with prolonged therapy and less frequent\ndosing.\n * MeaningfulConversionstoEASI-100: In maintenance, a 2- to 5-fold increase in\npercentage of patients who achieved EASI-100 was observed in the 24 µg/kg Q4W\nand Q12W dosing regimens. Among all re-randomized patients from Week 16 to\nWeek 52, Q4W maintenance dosing increased EASI-100 response from 4% to 22% and\nQ12W dosing increased EASI-100 response from 9% to 18%. Among re-randomized\npatients who had an EASI-75 or vIGA-AD response at maintenance baseline, Q4W\ndosing increased EASI-100 response from 6% to 30% and Q12W dosing increased\nEASI-100 response from 14% to 27%.\nAcross the REZOLVE-AD and REZOLVE-AA studies, rezpegaldesleukin's safety\nprofile through 52 weeks was favorable and consistent with the previously\nobserved and reported safety profile.(1-2)\n\nAdvancing into Phase 3 in Both Indications\n\n\"These results continue to grow the body of evidence that Treg stimulation is\nemerging as a durable and well-tolerated potential therapeutic option in two\ndistinct immune dermatologic patient populations and support\nrezpegaldesleukin's advancement into pivotal trials in both atopic dermatitis\nand alopecia areata,\" said Jonathan Zalevsky, Ph.D., Chief Research and\nDevelopment Officer at Nektar Therapeutics. \"We've now initiated the third\nPhase 3 study for rezpegaldesleukin in patients with moderate-to-severe atopic\ndermatitis who have had prior systemic biologic and/or JAK inhibitor treatment\nexperience and we are initiating the Phase 3 ZENITH AA study in alopecia\nareata in early 2027.\"\n\nConference Call and Webcast to Discuss Results Presented at EADV\n\nNektar management will host a conference call and live webcast today, October\n1, 2026, to review the results at 8:00 a.m. Eastern Time / 2:00 p.m. Central\nEuropean Time. Interested participants can access the live webcast at this\nLINK\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3765545642&u=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F427990780&a=LINK)\n.\n\nThe event, the press release and the slides will also be available on the\nevents section of the Nektar website at\nhttps://ir.nektar.com/events-and-presentations/events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1372581689&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4666649-1%26h%3D3890813892%26u%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents%26a%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents&a=https%3A%2F%2Fir.nektar.com%2Fevents-and-presentations%2Fevents)\n. A replay of the webcast will be available for at least 30 days following the\nevent.\n\nAbout REZOLVE-AA Phase 2b Study\n\nThe global 92-patient Phase 2b REZOLVE-AA (NCT06340360\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1807883179&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06340360&a=NCT06340360)\n) study was conducted in patients with severe-to-very-severe alopecia areata\nwho had not previously been treated with a JAK inhibitor or other biologic.\nDuring the initial 36-week induction phase, patients were randomized (3:3:2)\nto receive one of two rezpegaldesleukin doses or placebo, administered as\ntwice-monthly subcutaneous injections. Following completion of the induction\nphase, patients with a SALT Score greater than 20 at week 36 who also\ndemonstrated hair growth were eligible to continue on rezpegaldesleukin at\ntheir induction dose level in a blinded 16-week exploratory treatment\nextension through week 52. The primary endpoint was the mean percentage\nreduction from baseline in the Severity of Alopecia Tool (SALT) score at Week\n36. Key secondary endpoints included the proportion of patients who achieved\nabsolute SALT scores of less than or equal to 30, 20, and 10, along with the\nexploratory endpoint of the Clinician-Reported Outcomes (ClinRO) Eyebrow and\nEyelash Score.\n\nAbout REZOLVE-AD Phase 2b Study\n\nThe global 393-patient Phase 2b REZOLVE-AD (NCT06136741\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=2950150458&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06136741%3Fintr%3DREZOLVE-AD%26viewType%3DCard%26rank%3D1&a=NCT06136741)\n) study was conducted in patients with moderate-to-severe atopic dermatitis\nwho had not previously been treated with a JAK inhibitor or other biologic.\nPatients were randomized (3:3:3:2) to receive subcutaneous rezpegaldesleukin\nat one of three dose regimens: 24 µg/kg every two weeks (Q2W), 18 µg/kg Q2W,\nor 24 µg/kg every four weeks (Q4W). A fourth arm received placebo Q2W.\nPrimary and key secondary endpoints were assessed at Week 16. Following the\ninduction period, rezpegaldesleukin-treated patients who achieved EASI percent\nreductions of at least 50 were re-randomized (1:1) to continue at the same\ndose level on a Q4W or Q12W regimen through Week 52 in a blinded maintenance\nperiod. Placebo patients with EASI percent score reductions of at least 50\ncontinued to receive placebo Q4W.\n\nAbout Rezpegaldesleukin\n\nAutoimmune and inflammatory diseases cause the immune system to mistakenly\nattack and damage healthy cells in a person's body. A failure of the body's\nself-tolerance mechanisms enables the formation of the pathogenic T\nlymphocytes that conduct this attack. Rezpegaldesleukin is a potential\nfirst-in-class disease modifying therapeutic that may address this underlying\nimmune system imbalance in people with many autoimmune and inflammatory\nconditions. It targets the interleukin-2 receptor complex in the body to\nstimulate proliferation of powerful inhibitory immune cells known as\nregulatory Tcells. By activating these cells, rezpegaldesleukin may act to\nbring the immune system back into balance.\n\nIn February 2025, the U.S. FDA granted Fast Track designation for\nrezpegaldesleukin for the treatment of adult and pediatric patients 12 years\nof age and older with moderate-to-severe atopic dermatitis whose disease is\nnot adequately controlled with topical prescription therapies or when those\ntherapies are not advisable. In July 2025, the FDA granted Fast Track\ndesignation for rezpegaldesleukin for the treatment of severe alopecia areata\n(AA) in adults and pediatric patients 12 years of age and older who weigh at\nleast 40 kg.\n\nRezpegaldesleukin is being developed as a self-administered injection for a\nnumber of autoimmune and inflammatory diseases, including atopic dermatitis,\nalopecia areata and Type 1 diabetes. It is wholly owned by Nektar\nTherapeutics.\n\nAbout Alopecia Areata\n\nAlopecia areata is a disease where a patient's own immune system attacks hair\nfollicles resulting in hair loss.(3) The lifetime incidence of alopecia areata\nis 2% in both men and women.(3) Nearly 6.7 million people in the U.S. and 160\nmillion worldwide develop alopecia areata in their lifetime. About 700,000\npeople in the U.S. currently have some form of alopecia areata.(4) It is often\nassociated with other autoimmune conditions as well as depression and\nanxiety.(5 )The disease has a tremendous impact on quality of life for\npatients.(6) Available therapies for alopecia areata are not durable and have\nhigh relapse rates and there is an urgent unmet medical need for novel, more\neffective therapies for patients.\n\nAbout Atopic Dermatitis\n\nAtopic dermatitis is the most common type of eczema, affecting approximately\n30 million people in the United States.(6 )AD is characterized by a defect in\nthe skin barrier, which allows allergens and other irritants to enter the\nskin, leading to an immune reaction and inflammation.\n\nAbout Nektar Therapeutics\n\nNektar Therapeutics is a clinical-stage biotechnology company focused on\ndeveloping treatments that address the underlying immunological dysfunction in\nautoimmune and chronic inflammatory diseases. Nektar's lead product candidate,\nrezpegaldesleuki (REZPEG, or NKTR-358), is a novel, first-in-class regulatory\nT cell stimulator being evaluated in atopic dermatitis, alopecia areata, and\nType 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent\ntumor necrosis factor receptor type II (TNFR2) antibody and bispecific\nprograms, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony\nstimulating factor (CSF) protein, NKTR-422.\n\nNektar is headquartered in San Francisco, California. For further information,\nvisit www.nektar.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3558821494&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4620137-1%26h%3D4122722038%26u%3Dhttp%253A%252F%252Fwww.nektar.com%252F%26a%3Dwww.nektar.com&a=www.nektar.com)\nand follow us on LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements which can be identified\nby words such as: \"can,\" \"develop,\" \"potential,\" \"expand,\" \"address,\" \"may,\"\n\"plan,\" \"will\" and similar references to future periods. Examples of\nforward-looking statements include, among others, statements regarding the\nsafety and efficacy profile and therapeutic potential of, and future\ndevelopment plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422,\nand potential patient preferences and market adoption related thereto, and\nplans and timing of future data releases. Forward-looking statements are\nneither historical facts nor assurances of future performance. Instead, they\nare based only on our current beliefs, expectations and assumptions regarding\nthe future of our business, future plans and strategies, anticipated events\nand trends, the economy and other future conditions. Because forward-looking\nstatements relate to the future, they are subject to inherent uncertainties,\nrisks and changes in circumstances that are difficult to predict and many of\nwhich are outside of our control. Our actual results may differ materially\nfrom those indicated in the forward-looking statements. Therefore, you should\nnot rely on any of these forward-looking statements. Important factors that\ncould cause our actual results to differ materially from those indicated in\nthe forward-looking statements include, among others: (i) our statements\nregarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166\nand NKTR-422 are based on preclinical and clinical findings and observations\nand are subject to change as research and development continue; (ii)\nrezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational\nagents and continued research and development for these drug candidates is\nsubject to substantial risks, including negative safety and efficacy findings\nin future clinical studies (notwithstanding positive findings in earlier\npreclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165,\nNKTR-0166 and NKTR-422 are in clinical development and the risk of failure is\nhigh and can unexpectedly occur at any stage prior to regulatory approval;\n(iv) data reported from ongoing clinical trials are necessarily interim data\nonly and the final results will change based on continuing observations; (v)\nthe timing of the commencement or end of clinical trials and the availability\nof clinical data may be delayed or unsuccessful due to regulatory delays,\nslower than anticipated patient enrollment, manufacturing challenges, changing\nstandards of care, evolving regulatory requirements, clinical trial design,\nclinical outcomes, competitive factors, or delay or failure in ultimately\nobtaining regulatory approval in one or more important markets; (vi) a Fast\nTrack designation does not increase the likelihood that rezpegaldesleukin will\nreceive marketing approval in the United States; (vii) patents may not issue\nfrom our patent applications for our drug candidates, patents that have issued\nmay not be enforceable, or additional intellectual property licenses from\nthird parties may be required; and (viii) certain other important risks and\nuncertainties set forth in our Annual Report on Form 10-K filed with the\nSecurities and Exchange Commission on March 13, 2026 and our subsequent\nfilings. Any forward-looking statement made by us in this press release is\nbased only on information currently available to us and speaks only as of the\ndate on which it is made. We undertake no obligation to update any\nforward-looking statement, whether written or oral, that may be made from time\nto time, whether as a result of new information, future developments or\notherwise.\n\nContacts\n\nFor Investors:\n\nVivian Wu\n628-895-0661\nVWu@nektar.com (mailto:VWu@nektar.com)\n\nCorey Davis, Ph.D.\nLifeSci Advisors\n212-915-2577\ncdavis@lifesciadvisors.com (mailto:cdavis@lifesciadvisors.com)\n\nFor Media:\n\nSusan Roberts\nLifeSci Communications\n202-779-0929\nsroberts@lifescicomms.com (mailto:sroberts@lifescicomms.com)\n\n 1. Nektar Therapeutics. Investor Event: REZOLVE-AD Maintenance Data Update.\nFebruary 2026.\n 2. Nektar Therapeutics. Investor Event: REZOLVE-AA 52-Week Topline Results and\nTreatment Extension Update. April 2026.\n 3. Rosmarin et al. (2026, March 27-31). Novel Regulatory Tcell enhancing Biologic\nRezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity-Dependent\nTreatment Response in Moderate-to-Severe Atopic Dermatitis. 2026 American\nAcademy of Dermatology (AAD), Denver, Colorado\n 4. Lintzeri, D.A., Constantinou, A., Hillmann, K., Ghoreschi, K., Vogt, A. and\nBlume-Peytavi, U. (2022), Alopecia areata – Current understanding and\nmanagement. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 20:\n59-90.\nhttps://doi.org/10.1111/ddg.14689\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=915763717&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4667749-1%26h%3D1056578478%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.1111%252Fddg.14689%26a%3Dhttps%253A%252F%252Fdoi.org%252F10.1111%252Fddg.14689&a=https%3A%2F%2Fdoi.org%2F10.1111%2Fddg.14689)\n 5. National Alopecia Areata Foundation\n 6. Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia Areata: Burden of\nDisease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig\nDermatol. 2023;16:803-820\nhttps://doi.org/10.2147/CCID.S376096\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=2340900279&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4667749-1%26h%3D422862988%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.2147%252FCCID.S376096%26a%3Dhttps%253A%252F%252Fdoi.org%252F10.2147%252FCCID.S376096&a=https%3A%2F%2Fdoi.org%2F10.2147%2FCCID.S376096)\n 7. Eczemastats.NationalEczemaAssociation.(2022,September 27).\nhttps://nationaleczema.org/research/eczema-facts/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3452326951&u=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F&a=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F)\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/new-rezpegaldesleukin-data-supporting-long-term-durability-and-disease-improvement-in-patients-with-alopecia-areata-and-atopic-dermatitis-at-eadv-congress-2026-302895848.html\n(https://www.prnewswire.com/news-releases/new-rezpegaldesleukin-data-supporting-long-term-durability-and-disease-improvement-in-patients-with-alopecia-areata-and-atopic-dermatitis-at-eadv-congress-2026-302895848.html)\n\nSOURCE Nektar Therapeutics\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS565268/Nektar-Logo-v1.jpg?id=OA2978496\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5WJXsKa-20261001","title":"New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026","author":"PR Newswire","ticker":"NKTR","created":"2026-10-01T11:30:02.062Z","tickers":["NKTR"],"exchange":"NASDAQ","article_body":"New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026\nPR Newswire\n\nSAN FRANCISCO and VIENNA, Oct. 1, 2026\n\nRezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year\nof treatment in two dermatological indications, reinforcing the differentiated\nproperties of this novel Treg mechanism\n\nIn alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4\nmonths off treatment and in 63% at six months off treatment\n\nHair regrowth continued for 6 months off treatment with 19% of patients\nachieving SALT Score ≤10, an improvement from 7% at the end of 52 weeks of\ntreatment\n\nThird Phase 3 study in the global ZENITH AD program initiated, expanding the\nprogram into treatment-experiencedatopicdermatitispatients;\nPhase3ZENITHAAstudytoinitiate in early 2027\n\nCompanytohostconferencecallwithinvestorsandanalystsat8:00AMET/2:00 PM CET\n\nSAN FRANCISCO and VIENNA, Oct. 1, 2026 /PRNewswire/ -- Nektar Therapeutics\n(Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from\nthe Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at\nthe European Academy of Dermatology and Venereology (EADV) Congress 2026 in\nVienna, Austria in two oral presentation sessions.\n\nAt EADV 2026, data from the 52-week treatment extension cohort and the 6-month\noff-treatment period in the global Phase 2b REZOLVE-AA study in patients with\nsevere-to-very-severe alopecia areata are being presented by Dr. David\nRosmarin, Chair of Dermatology, Indiana University School of Medicine in an\noral presentation entitled\n\"Rezpegaldesleukin,aNovelRegulatoryTCell-InducingBiologic,Demonstrates\nEfficacy and Safety in Severe-to-Very-Severe Alopecia Areata: 52-Week Results\nfrom the Phase 2b REZOLVE-AA Study\" [link to presentation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3105107766&u=https%3A%2F%2Fwww.nektar.com%2Fwp-content%2Fuploads%2F2026%2F10%2FEADV-2026_Rosmarin_Rezpegaldesleukin_Rezolve_AA.pdf&a=link+to+presentation)\n].\n\n\"These data demonstrate that one year of treatment with rezpegaldesleukin can\nresult in lasting and even deepening hair regrowth with these same effects\ncontinuing for six months off-treatment in the majority of patients,\" said\nDavid Rosmarin, M.D., Chair of the Department of Dermatology and Associate\nProfessor of Dermatology at Indiana University School of Medicine. \"As a novel\nTreg-targeted mechanism, rezpegaldesleukin is designed to address the\nunderlying immune dysregulation in patients with alopecia areata. To date, we\nhave not seen this degree of both sustained benefit and further hair regrowth\nafter treatment cessation with existing systemic therapies for alopecia\nareata. These findings suggest that rezpegaldesleukin may offer a\nfundamentally different approach to managing this chronic disorder and could\nemerge as a preferred first-line treatment option in the future for patients\nseeking durable disease control.\"\n\nHighlights from 52-Week Results in REZOLVE-AA Phase 2b Study in Alopecia\nAreata (Including Off-Treatment Durability):\n\n * A total of 31 patients continued into a blinded 16-week treatment extension\nafter 36 weeks of initial treatment with 27 patients in the twice-monthly\nrezpegaldesleukin dose arms (low dose of 18 µg/kg, n=14) and (high dose of 24\nµg/kg, n=13).\n * As previously reported, continued rezpegaldesleukin treatment through Week 52\ndemonstrated clear and consistent separation from placebo on key measures of\nefficacy. From Week 36 to Week 52, 29% of patients at low dose and 31% of\npatients at high dose achieved new SALT Score ≤20 responses as compared to\nnone in the placebo arm. A SALT Score ≤20 is achieved when a patient has 80%\nor more of their scalp covered by hair.\n * SimilarEfficacy Demonstrated in Patients Irrespective of Duration of Current\nEpisode: A new subgroup analysis of all patients who entered the 52-week\ntreatment extension showed similar efficacy data regardless of current\nalopecia areata episode duration. SALT Score ≤20 responses were achieved by\n29% and 30% of patients whose current episode was less than four years and\nthose whose current episode was four years or longer, respectively.\n * Off-Treatment Durability: Patients treated for 52 weeks showed 75% (6/8)\nmaintenance of SALT Score ≤20 after 4 months off treatment and 63% (5/8)\nmaintenance of SALT Score ≤20 after 6 months off treatment.\n * Off-Treatment Deepening: SALT Score ≤10 responses deepened in the 6-month\noff-treatment follow-up period from 7% at the end of treatment at week 52 to\n19% after 6 months off treatment.\n * Potential for Less Frequent Monthly Dosing Beyond One Year of Treatment: Data\nsupport evaluation of monthly (Q4W) or quarterly (Q12W) dosing beyond the\n52-week twice-monthly (Q2W) induction dosing for patients who achieve a SALT\nScore ≤20.\n * Phase 3 Study to Initiate in Early 2027: ZENITH AA study will be conducted in\n850 patients with severe-to-very-severe alopecia areata with a primary\nendpoint of SALT Score ≤20 at Week 52.\nAlso, at EADV 2026, datafromthemaintenanceperiodoftheREZOLVE-ADstudy in\nmoderate-to-severe atopic dermatitis patients who were treated with monthly\nand quarterly dosing regimens for up to 52 weeks were presented by Dr. Thomas\nBieber, Professor, Department of Dermatology and Allergy, Ludwig-Maximilians\nUniversity Hospital, Munich, Germany in an oral presentation entitled\n\"RezpegaldesleukinProvidesDurableandDeepeningImprovementsintheSignsand\nSymptoms of Atopic Dermatitis with Monthly and Quarterly Dosing: Results from\nthe Phase 2b REZOLVE-AD Maintenance Part of Study\" [link to presentation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1963735054&u=https%3A%2F%2Fwww.nektar.com%2Fwp-content%2Fuploads%2F2026%2F10%2FEADV-2026_Silverberg_Rezpegaldesleukin_Rezolve_AD.pdf&a=link+to+presentation)\n].\n\n\"Rezpegaldesleukin demonstrated a high maintenance of response and further\ndeepening of response that speaks to the unique therapeutic approach of a\nregulatory Tcell agonist in patients with atopic dermatitis,\" said Thomas\nBieber, M.D., Ph.D., Professor, Department of Dermatology and Allergy,\nLudwig-Maximilians University Hospital, Munich, Germany. \"With both monthly\nand quarterly maintenance dosing, new and sustained responses were observed\nacross the key endpoints of EASI-75, vIGA-AD 0/1 and Itch NRS, with some\npatients achieving complete skin clearance, or EASI-100. These novel data\nsupport the ongoing Phase 3 studies and also highlight the importance of a\nTreg mechanism to address the heterogeneity of disease in atopic dermatitis\npatients.\"\n\nHighlights from Week 52 REZOLVE-AD Maintenance Period in Atopic Dermatitis:\n\n * DurabilityofTreatmentEffect: Q4W and Q12W dosing regimens resulted in\nsustained disease control for at least a 75% improvement in the Eczema Area\nand Severity Index (EASI-75), at least a 90% improvement in the Eczema Area\nand Severity Index (EASI-90), validated Investigator Global Assessment of\nAtopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS)\nresponse, with the 24 µg/kg Q4W and Q12W regimens showing the highest\nmaintenance of response at Week 52.\n * New and Deepening of Response Over Time: A meaningful proportion of patients\nachieved new EASI-75, EASI-90, Itch NRS and vIGA-AD 0/1 responses at Week 52,\nsupporting increased disease control with prolonged therapy and less frequent\ndosing.\n * MeaningfulConversionstoEASI-100: In maintenance, a 2- to 5-fold increase in\npercentage of patients who achieved EASI-100 was observed in the 24 µg/kg Q4W\nand Q12W dosing regimens. Among all re-randomized patients from Week 16 to\nWeek 52, Q4W maintenance dosing increased EASI-100 response from 4% to 22% and\nQ12W dosing increased EASI-100 response from 9% to 18%. Among re-randomized\npatients who had an EASI-75 or vIGA-AD response at maintenance baseline, Q4W\ndosing increased EASI-100 response from 6% to 30% and Q12W dosing increased\nEASI-100 response from 14% to 27%.\nAcross the REZOLVE-AD and REZOLVE-AA studies, rezpegaldesleukin's safety\nprofile through 52 weeks was favorable and consistent with the previously\nobserved and reported safety profile.(1-2)\n\nAdvancing into Phase 3 in Both Indications\n\n\"These results continue to grow the body of evidence that Treg stimulation is\nemerging as a durable and well-tolerated potential therapeutic option in two\ndistinct immune dermatologic patient populations and support\nrezpegaldesleukin's advancement into pivotal trials in both atopic dermatitis\nand alopecia areata,\" said Jonathan Zalevsky, Ph.D., Chief Research and\nDevelopment Officer at Nektar Therapeutics. \"We've now initiated the third\nPhase 3 study for rezpegaldesleukin in patients with moderate-to-severe atopic\ndermatitis who have had prior systemic biologic and/or JAK inhibitor treatment\nexperience and we are initiating the Phase 3 ZENITH AA study in alopecia\nareata in early 2027.\"\n\nConference Call and Webcast to Discuss Results Presented at EADV\n\nNektar management will host a conference call and live webcast today, October\n1, 2026, to review the results at 8:00 a.m. Eastern Time / 2:00 p.m. Central\nEuropean Time. Interested participants can access the live webcast at this\nLINK\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3765545642&u=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F427990780&a=LINK)\n.\n\nThe event, the press release and the slides will also be available on the\nevents section of the Nektar website at\nhttps://ir.nektar.com/events-and-presentations/events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1372581689&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4666649-1%26h%3D3890813892%26u%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents%26a%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents&a=https%3A%2F%2Fir.nektar.com%2Fevents-and-presentations%2Fevents)\n. A replay of the webcast will be available for at least 30 days following the\nevent.\n\nAbout REZOLVE-AA Phase 2b Study\n\nThe global 92-patient Phase 2b REZOLVE-AA (NCT06340360\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=1807883179&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06340360&a=NCT06340360)\n) study was conducted in patients with severe-to-very-severe alopecia areata\nwho had not previously been treated with a JAK inhibitor or other biologic.\nDuring the initial 36-week induction phase, patients were randomized (3:3:2)\nto receive one of two rezpegaldesleukin doses or placebo, administered as\ntwice-monthly subcutaneous injections. Following completion of the induction\nphase, patients with a SALT Score greater than 20 at week 36 who also\ndemonstrated hair growth were eligible to continue on rezpegaldesleukin at\ntheir induction dose level in a blinded 16-week exploratory treatment\nextension through week 52. The primary endpoint was the mean percentage\nreduction from baseline in the Severity of Alopecia Tool (SALT) score at Week\n36. Key secondary endpoints included the proportion of patients who achieved\nabsolute SALT scores of less than or equal to 30, 20, and 10, along with the\nexploratory endpoint of the Clinician-Reported Outcomes (ClinRO) Eyebrow and\nEyelash Score.\n\nAbout REZOLVE-AD Phase 2b Study\n\nThe global 393-patient Phase 2b REZOLVE-AD (NCT06136741\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=2950150458&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06136741%3Fintr%3DREZOLVE-AD%26viewType%3DCard%26rank%3D1&a=NCT06136741)\n) study was conducted in patients with moderate-to-severe atopic dermatitis\nwho had not previously been treated with a JAK inhibitor or other biologic.\nPatients were randomized (3:3:3:2) to receive subcutaneous rezpegaldesleukin\nat one of three dose regimens: 24 µg/kg every two weeks (Q2W), 18 µg/kg Q2W,\nor 24 µg/kg every four weeks (Q4W). A fourth arm received placebo Q2W.\nPrimary and key secondary endpoints were assessed at Week 16. Following the\ninduction period, rezpegaldesleukin-treated patients who achieved EASI percent\nreductions of at least 50 were re-randomized (1:1) to continue at the same\ndose level on a Q4W or Q12W regimen through Week 52 in a blinded maintenance\nperiod. Placebo patients with EASI percent score reductions of at least 50\ncontinued to receive placebo Q4W.\n\nAbout Rezpegaldesleukin\n\nAutoimmune and inflammatory diseases cause the immune system to mistakenly\nattack and damage healthy cells in a person's body. A failure of the body's\nself-tolerance mechanisms enables the formation of the pathogenic T\nlymphocytes that conduct this attack. Rezpegaldesleukin is a potential\nfirst-in-class disease modifying therapeutic that may address this underlying\nimmune system imbalance in people with many autoimmune and inflammatory\nconditions. It targets the interleukin-2 receptor complex in the body to\nstimulate proliferation of powerful inhibitory immune cells known as\nregulatory Tcells. By activating these cells, rezpegaldesleukin may act to\nbring the immune system back into balance.\n\nIn February 2025, the U.S. FDA granted Fast Track designation for\nrezpegaldesleukin for the treatment of adult and pediatric patients 12 years\nof age and older with moderate-to-severe atopic dermatitis whose disease is\nnot adequately controlled with topical prescription therapies or when those\ntherapies are not advisable. In July 2025, the FDA granted Fast Track\ndesignation for rezpegaldesleukin for the treatment of severe alopecia areata\n(AA) in adults and pediatric patients 12 years of age and older who weigh at\nleast 40 kg.\n\nRezpegaldesleukin is being developed as a self-administered injection for a\nnumber of autoimmune and inflammatory diseases, including atopic dermatitis,\nalopecia areata and Type 1 diabetes. It is wholly owned by Nektar\nTherapeutics.\n\nAbout Alopecia Areata\n\nAlopecia areata is a disease where a patient's own immune system attacks hair\nfollicles resulting in hair loss.(3) The lifetime incidence of alopecia areata\nis 2% in both men and women.(3) Nearly 6.7 million people in the U.S. and 160\nmillion worldwide develop alopecia areata in their lifetime. About 700,000\npeople in the U.S. currently have some form of alopecia areata.(4) It is often\nassociated with other autoimmune conditions as well as depression and\nanxiety.(5 )The disease has a tremendous impact on quality of life for\npatients.(6) Available therapies for alopecia areata are not durable and have\nhigh relapse rates and there is an urgent unmet medical need for novel, more\neffective therapies for patients.\n\nAbout Atopic Dermatitis\n\nAtopic dermatitis is the most common type of eczema, affecting approximately\n30 million people in the United States.(6 )AD is characterized by a defect in\nthe skin barrier, which allows allergens and other irritants to enter the\nskin, leading to an immune reaction and inflammation.\n\nAbout Nektar Therapeutics\n\nNektar Therapeutics is a clinical-stage biotechnology company focused on\ndeveloping treatments that address the underlying immunological dysfunction in\nautoimmune and chronic inflammatory diseases. Nektar's lead product candidate,\nrezpegaldesleuki (REZPEG, or NKTR-358), is a novel, first-in-class regulatory\nT cell stimulator being evaluated in atopic dermatitis, alopecia areata, and\nType 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent\ntumor necrosis factor receptor type II (TNFR2) antibody and bispecific\nprograms, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony\nstimulating factor (CSF) protein, NKTR-422.\n\nNektar is headquartered in San Francisco, California. For further information,\nvisit www.nektar.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3558821494&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4620137-1%26h%3D4122722038%26u%3Dhttp%253A%252F%252Fwww.nektar.com%252F%26a%3Dwww.nektar.com&a=www.nektar.com)\nand follow us on LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements which can be identified\nby words such as: \"can,\" \"develop,\" \"potential,\" \"expand,\" \"address,\" \"may,\"\n\"plan,\" \"will\" and similar references to future periods. Examples of\nforward-looking statements include, among others, statements regarding the\nsafety and efficacy profile and therapeutic potential of, and future\ndevelopment plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422,\nand potential patient preferences and market adoption related thereto, and\nplans and timing of future data releases. Forward-looking statements are\nneither historical facts nor assurances of future performance. Instead, they\nare based only on our current beliefs, expectations and assumptions regarding\nthe future of our business, future plans and strategies, anticipated events\nand trends, the economy and other future conditions. Because forward-looking\nstatements relate to the future, they are subject to inherent uncertainties,\nrisks and changes in circumstances that are difficult to predict and many of\nwhich are outside of our control. Our actual results may differ materially\nfrom those indicated in the forward-looking statements. Therefore, you should\nnot rely on any of these forward-looking statements. Important factors that\ncould cause our actual results to differ materially from those indicated in\nthe forward-looking statements include, among others: (i) our statements\nregarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166\nand NKTR-422 are based on preclinical and clinical findings and observations\nand are subject to change as research and development continue; (ii)\nrezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational\nagents and continued research and development for these drug candidates is\nsubject to substantial risks, including negative safety and efficacy findings\nin future clinical studies (notwithstanding positive findings in earlier\npreclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165,\nNKTR-0166 and NKTR-422 are in clinical development and the risk of failure is\nhigh and can unexpectedly occur at any stage prior to regulatory approval;\n(iv) data reported from ongoing clinical trials are necessarily interim data\nonly and the final results will change based on continuing observations; (v)\nthe timing of the commencement or end of clinical trials and the availability\nof clinical data may be delayed or unsuccessful due to regulatory delays,\nslower than anticipated patient enrollment, manufacturing challenges, changing\nstandards of care, evolving regulatory requirements, clinical trial design,\nclinical outcomes, competitive factors, or delay or failure in ultimately\nobtaining regulatory approval in one or more important markets; (vi) a Fast\nTrack designation does not increase the likelihood that rezpegaldesleukin will\nreceive marketing approval in the United States; (vii) patents may not issue\nfrom our patent applications for our drug candidates, patents that have issued\nmay not be enforceable, or additional intellectual property licenses from\nthird parties may be required; and (viii) certain other important risks and\nuncertainties set forth in our Annual Report on Form 10-K filed with the\nSecurities and Exchange Commission on March 13, 2026 and our subsequent\nfilings. Any forward-looking statement made by us in this press release is\nbased only on information currently available to us and speaks only as of the\ndate on which it is made. We undertake no obligation to update any\nforward-looking statement, whether written or oral, that may be made from time\nto time, whether as a result of new information, future developments or\notherwise.\n\nContacts\n\nFor Investors:\n\nVivian Wu\n628-895-0661\nVWu@nektar.com (mailto:VWu@nektar.com)\n\nCorey Davis, Ph.D.\nLifeSci Advisors\n212-915-2577\ncdavis@lifesciadvisors.com (mailto:cdavis@lifesciadvisors.com)\n\nFor Media:\n\nSusan Roberts\nLifeSci Communications\n202-779-0929\nsroberts@lifescicomms.com (mailto:sroberts@lifescicomms.com)\n\n 1. Nektar Therapeutics. Investor Event: REZOLVE-AD Maintenance Data Update.\nFebruary 2026.\n 2. Nektar Therapeutics. Investor Event: REZOLVE-AA 52-Week Topline Results and\nTreatment Extension Update. April 2026.\n 3. Rosmarin et al. (2026, March 27-31). Novel Regulatory Tcell enhancing Biologic\nRezpegaldesleukin: Phase 2b Efficacy, Safety, and Baseline Severity-Dependent\nTreatment Response in Moderate-to-Severe Atopic Dermatitis. 2026 American\nAcademy of Dermatology (AAD), Denver, Colorado\n 4. Lintzeri, D.A., Constantinou, A., Hillmann, K., Ghoreschi, K., Vogt, A. and\nBlume-Peytavi, U. (2022), Alopecia areata – Current understanding and\nmanagement. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 20:\n59-90.\nhttps://doi.org/10.1111/ddg.14689\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=915763717&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4667749-1%26h%3D1056578478%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.1111%252Fddg.14689%26a%3Dhttps%253A%252F%252Fdoi.org%252F10.1111%252Fddg.14689&a=https%3A%2F%2Fdoi.org%2F10.1111%2Fddg.14689)\n 5. National Alopecia Areata Foundation\n 6. Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia Areata: Burden of\nDisease, Approach to Treatment, and Current Unmet Needs. Clin Cosmet Investig\nDermatol. 2023;16:803-820\nhttps://doi.org/10.2147/CCID.S376096\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=2340900279&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4667749-1%26h%3D422862988%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.2147%252FCCID.S376096%26a%3Dhttps%253A%252F%252Fdoi.org%252F10.2147%252FCCID.S376096&a=https%3A%2F%2Fdoi.org%2F10.2147%2FCCID.S376096)\n 7. Eczemastats.NationalEczemaAssociation.(2022,September 27).\nhttps://nationaleczema.org/research/eczema-facts/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786161-1&h=3452326951&u=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F&a=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F)\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/new-rezpegaldesleukin-data-supporting-long-term-durability-and-disease-improvement-in-patients-with-alopecia-areata-and-atopic-dermatitis-at-eadv-congress-2026-302895848.html\n(https://www.prnewswire.com/news-releases/new-rezpegaldesleukin-data-supporting-long-term-durability-and-disease-improvement-in-patients-with-alopecia-areata-and-atopic-dermatitis-at-eadv-congress-2026-302895848.html)\n\nSOURCE Nektar Therapeutics\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS565268/Nektar-Logo-v1.jpg?id=OA2978496\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-01T11:30:02.340569386Z","server_sent_at_ms":1790854202340},"received_at":"2026-10-01T11:30:02.391Z","source_url":"https://www.prnewswire.com/news-releases/new-rezpegaldesleukin-data-supporting-long-term-durability-and-disease-improvement-in-patients-with-alopecia-areata-and-atopic-dermatitis-at-eadv-congress-2026-302895848.html"},"analysis":{"id":"146601","press_release_id":"157953","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Nektar presented long-term Phase 2b data at EADV 2026 showing rezpegaldesleukin's durability in alopecia areata and atopic dermatitis, with SALT ≤20 responses maintained in 75% of AA patients at 4 months and 63% at 6 months off treatment.\n\nHair regrowth deepened off-treatment — SALT ≤10 responses rose from 7% at end of Week 52 to 19% after 6 months off — while AD maintenance data showed EASI-100 responses climbing as much as 4-fold under Q4W/Q12W dosing.\n\nNektar initiated a third Phase 3 ZENITH AD study in treatment-experienced patients and plans to launch the Phase 3 ZENITH AA study (850 patients) in early 2027, advancing its lead wholly-owned asset in both indications.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Off-treatment durability and deepening response differentiate REZPEG from JAK inhibitors ahead of two Phase 3 launches."},"keyFigures":{"drugName":"rezpegaldesleukin (REZPEG, NKTR-358)","phaseOfTrial":"Phase 2b","customDimensions":{"zenith_aa_enrollment":850,"zenith_aa_initiation":"early 2027","easi100_q4w_responders":"6% to 30%","easi100_q12w_responders":"14% to 27%","easi100_q4w_all_patients":"4% to 22%","salt10_off_treatment_6mo":"19% (up from 7% at Week 52)","easi100_q12w_all_patients":"9% to 18%","salt20_off_treatment_maintenance_4mo":"75% (6/8)","salt20_off_treatment_maintenance_6mo":"63% (5/8)"}},"quotedText":"we have not seen this degree of both sustained benefit and further hair regrowth after treatment cessation with existing systemic therapies for alopecia areata","namedEntities":{"people":[{"name":"David Rosmarin, M.D.","role":"Chair of Dermatology, Indiana University School of Medicine; REZOLVE-AA presenter"},{"name":"Thomas Bieber, M.D., Ph.D.","role":"Professor of Dermatology and Allergy, Ludwig-Maximilians University Hospital, Munich; REZOLVE-AD presenter"},{"name":"Jonathan Zalevsky, Ph.D.","role":"Chief Research and Development Officer, Nektar Therapeutics"}],"products":["rezpegaldesleukin (REZPEG / NKTR-358)","NKTR-0165","NKTR-0166","NKTR-422"],"companies":[{"name":"Nektar Therapeutics","ticker":"NKTR","relationship":"filer"},{"name":"European Academy of Dermatology and Venereology (EADV)","relationship":"conference host"},{"name":"Indiana University School of Medicine","relationship":"investigator institution"},{"name":"Ludwig-Maximilians University Hospital, Munich","relationship":"investigator institution"},{"name":"LifeSci Advisors","relationship":"IR agency"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Phase 2b durability data for rezpegaldesleukin in alopecia areata and atopic dermatitis support Phase 3 advancement, with a third ZENITH AD study initiated and ZENITH AA slated for early 2027. Material de-risking for the lead asset, though not a binary regulatory event."},"tickerRelevance":{"others":[],"primary":"NKTR"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap clinical-stage biotech","binaryEvent":false,"eventGravity":"positive Phase 2b data supporting Phase 3 advancement","retailFavoriteBoost":"moderate — NKTR has a retail following in biotech"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Nektar presented long-term Phase 2b data at EADV 2026 showing rezpegaldesleukin's durability in alopecia areata and atopic dermatitis, with SALT ≤20 responses maintained in 75% of AA patients at 4 months and 63% at 6 months off treatment.\n\nHair regrowth deepened off-treatment — SALT ≤10 responses rose from 7% at end of Week 52 to 19% after 6 months off — while AD maintenance data showed EASI-100 responses climbing as much as 4-fold under Q4W/Q12W dosing.\n\nNektar initiated a third Phase 3 ZENITH AD study in treatment-experienced patients and plans to launch the Phase 3 ZENITH AA study (850 patients) in early 2027, advancing its lead wholly-owned asset in both indications.","key_figures":{"drugName":"rezpegaldesleukin (REZPEG, NKTR-358)","phaseOfTrial":"Phase 2b","customDimensions":{"zenith_aa_enrollment":850,"zenith_aa_initiation":"early 2027","easi100_q4w_responders":"6% to 30%","easi100_q12w_responders":"14% to 27%","easi100_q4w_all_patients":"4% to 22%","salt10_off_treatment_6mo":"19% (up from 7% at Week 52)","easi100_q12w_all_patients":"9% to 18%","salt20_off_treatment_maintenance_4mo":"75% (6/8)","salt20_off_treatment_maintenance_6mo":"63% (5/8)"}},"named_entities":{"people":[{"name":"David Rosmarin, M.D.","role":"Chair of Dermatology, Indiana University School of Medicine; REZOLVE-AA presenter"},{"name":"Thomas Bieber, M.D., Ph.D.","role":"Professor of Dermatology and Allergy, Ludwig-Maximilians University Hospital, Munich; REZOLVE-AD presenter"},{"name":"Jonathan Zalevsky, Ph.D.","role":"Chief Research and Development Officer, Nektar Therapeutics"}],"products":["rezpegaldesleukin (REZPEG / NKTR-358)","NKTR-0165","NKTR-0166","NKTR-422"],"companies":[{"name":"Nektar Therapeutics","ticker":"NKTR","relationship":"filer"},{"name":"European Academy of Dermatology and Venereology (EADV)","relationship":"conference host"},{"name":"Indiana University School of Medicine","relationship":"investigator institution"},{"name":"Ludwig-Maximilians University Hospital, Munich","relationship":"investigator institution"},{"name":"LifeSci Advisors","relationship":"IR agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T11:30:17.208Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap clinical-stage biotech","binaryEvent":false,"eventGravity":"positive Phase 2b data supporting Phase 3 advancement","retailFavoriteBoost":"moderate — NKTR has a retail following in biotech"}},"durationMs":7134,"modelName":"glm-5.3-flashx"}}